Ardelyx
Ardelyx Inc is an American commercial-stage biopharmaceutical enterprise specializing in the discovery, development, and commercialization of innovative first-in-class medicines targeting gastrointestinal and cardiorenal diseases, prominently featuring FDA-approved commercial products such as Xphozah (tenapanor for hyperphosphatemia in chronic kidney disease) and Ibsrela (tenapanor for irritable bowel syndrome with constipation). The company conducts advanced pharmaceutical research and commercial sales operations supplying specialty medicines to patients, nephrologists, and gastroenterologists across the United States. Its core business operations encompass biopharmaceutical research, clinical drug development, FDA regulatory navigation, and commercial pharmaceutical sales. Revenue is derived primarily from the commercial prescription sales of Xphozah and Ibsrela in the United States. Ardelyx holds a leading market position in cardiorenal and gastrointestinal therapeutics. The company is headquartered in Waltham, Massachusetts, United States, and its common stock trades on the Nasdaq Global Select Market under the ticker ARDX.
2 of the funds FundTelligence covers report a position in Ardelyx.
- Legal name
- Ardelyx Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 2
Funds holding Ardelyx
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.05 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)